Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Brought to you by:
Cell & Gene Therapy
Biotech
BioMarin drops PKU drug once seen as possible Palynziq successor
BioMarin is continuing to slim down its pipeline, this time ending work on a preclinical PKU drug once touted as a potential successor to Palynziq.
James Waldron
Aug 5, 2025 4:48am
Charles River explores crowdfunding for cell and gene incubator
Aug 4, 2025 2:55pm
Allogene reports patient death tied to mAb in CAR-T pivotal trial
Aug 1, 2025 8:30am
4DMT climbs as gene therapy patients keep jettisoning jabs
Aug 1, 2025 5:35am
Fierce Pharma
Prasad exit signals more permissive FDA for cell and gene field
Jul 31, 2025 9:10am
Fierce Pharma
Vinay Prasad departs FDA amid controversy over gene therapy
Jul 30, 2025 9:33am
More News
AstraZeneca drops lead TCR therapy from $200M Neogene buy
Jul 29, 2025 4:13am
Arrowhead meets $100M milestone, awaits Sarepta payment
Jul 28, 2025 3:10pm
Cell therapy biotech keeps adapting, selling 4 programs for $55M
Jul 28, 2025 10:52am
Elevidys fallout hasn't dented Roche's hopes for gene therapies
Jul 25, 2025 8:30am
See more stories
